Adalgur N

Method of action: Analgesic, Muscle Relaxant

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adalgur N

Adalgur N is a combination medication containing a common pain reliever and a muscle relaxant, designed to address discomfort associated with muscle stiffness. It is identified as a brand with this specific fixed-dose formulation in countries like Portugal.

Property	Description
Active ingredient	Paracetamol (Acetaminophen) and Thiocolchicoside
Form	Tablet (solid oral dosage)
Pharmacological class	Analgesic and Centrally Acting Muscle Relaxant
Common use	Relief of painful muscle contractures/spasms
Origin	Semi-synthetic derivative (Thiocolchicoside component)

What type of medicine is Adalgur N?

Adalgur N is a commercial combination product that delivers two distinct therapeutic actions through a single formulation: it acts as both an analgesic and a centrally acting muscle relaxant. It is typically supplied as a tablet for oral administration. The World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system places the Thiocolchicoside component within the broader category of muscle relaxants.

Pharmacological studies have explored the use of combined therapies like this for improving patient comfort where muscle spasm is involved. This approach is intended to address the spasm-pain cycle simultaneously.

Composition: What Active Ingredients Does It Contain?

The two main active ingredients are Paracetamol (a synthetic compound) and Thiocolchicoside. Paracetamol is included for its widely known general pain-relieving effect. Thiocolchicoside is the component that functions as the muscle relaxant, targeting the central nervous system to help ease stiff, contracted muscles. The use of Thiocolchicoside is recognized in pharmaceutical guidelines as an adjuvant treatment for acute muscle stiffness in adults. This confirms the specific role of the Thiocolchicoside component within the medicine.

General Purpose: Why is this Combination Used?

The general purpose of Adalgur N is to address musculoskeletal discomfort associated with uncontrolled muscle stiffness or spasms. This combination strategy is used for providing pain relief and functional outcomes compared to using a pain reliever alone, especially in cases of acute backache. This approach aims to interrupt the cycle where muscle tension causes pain, which, in turn, can cause more muscle tension, thus facilitating easier movement and greater comfort.

What side effects are possible with Adalgur N?

The safety profile of Adalgur N, a combination of Paracetamol and Thiocolchicoside, is established by regulatory documents that classify potential adverse reactions based on incidence and physiological system involvement.

Adverse Reaction Scope

Classification	Examples of Documented Adverse Reactions
Common	Somnolence (drowsiness), Diarrhea, Stomach pain (Gastralgia)
Uncommon	Urticaria (hives), Pruritus (itching)
Rare	Anaphylactic reaction, Severe hepatic injury
System-Organ Classes	Nervous System Disorders, Immune System Disorders, Hepatobiliary Disorders

Serious Adverse Reactions and Safety Constraints

Regulatory labeling notes that serious adverse reactions, although rare, include Severe Hepatic Injury/Failure (a known risk of the Paracetamol component) and Anaphylactic Shock (a severe hypersensitivity reaction). Convulsions have also been documented as a possible serious adverse reaction.

The official prescribing information includes explicit safety constraints, particularly regarding the Thiocolchicoside component. Regulatory mandates restrict the duration of oral treatment to a maximum of seven consecutive days due to the concern over a metabolite's potential to cause chromosome number changes (aneuploidy).

Population-Specific Safety Considerations

The use of this medicine is contraindicated in specific populations: pregnant or breastfeeding women, and women of childbearing potential not using effective contraception. Caution is also typically advised in patients with severe hepatic or renal impairment due to potential alterations in clearance and organ-specific risk.

Connection to the Overall Safety Profile

The official safety profile structures the understanding of risk into two key areas: the potential for common central nervous system and gastrointestinal effects, and the potential for rare but serious organ-specific injury (liver). The primary structure is defined by the regulatory requirement to limit exposure duration due to genotoxicity concerns, which dictates the strict short-term use mandate across all approved labels.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Adalgur N overdose is dictated primarily by the acute toxicity risk associated with the Paracetamol component. In the event of an overdose, a severe, time-dependent risk of acute liver failure and potentially death exists.

Documented Overdose Manifestations and Actions

Initial signs of overdose may include nausea, vomiting, loss of appetite, sweating, and upper abdominal pain. Crucially, symptoms may be mild or absent for 24 hours despite the occurrence of serious hepatic injury. Later manifestations, such as jaundice (yellowing of the skin) and confusion, signal advanced toxicity.

Severe Regulatory Outcome	Required Emergency Action
Acute Liver Failure	Seek immediate medical attention
Death is a documented risk	Contact Poison Help or Emergency Services

Regulatory authorities mandate that immediate medical management is required in the event of suspected overdose, even if the person feels well. The specific antidote, N-Acetylcysteine, is indicated, and its effectiveness is greatest when administered within the critical first eight hours post-ingestion. Hospital monitoring is required, as laboratory evidence of liver injury may be delayed. Individuals with underlying liver disease or chronic heavy alcohol use face an increased risk of severe toxicity.

Therapeutic Uses of Adalgur N

What Adalgur N Treats: Main Uses and Benefits

Adalgur N is relevant for managing symptoms related to physical discomfort, in situations involving certain distressing symptoms. Its use is for easing symptoms like acute low back pain (lumbago) and cervical pain. The medication is applied in addressing symptom clusters where pain is combined with involuntary muscle stiffness and contractures.

Quick Fact: Relief for Painful Muscle Spasms

The combination is commonly used across conditions presenting with acute episodes of localized discomfort, including those associated with temporary functional strain. The medication is applied to address symptoms related to physical discomfort commonly seen in conditions such as low back pain or neck stiffness. This short-term symptomatic assistance is part of symptomatic management in clinical settings that involve acute or unstable symptom patterns. It is generally applied during phases of increased distress or discomfort, and plays a role in managing conditions characterized by periods of heightened symptoms.

“This supportive therapy assists with maintaining functional stability and provides support that helps ease the overall symptom burden.”

This assists with maintaining functional stability and supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

This section outlines the official population eligibility and non-eligibility rules for Adalgur N (adalimumab), strictly based on government regulatory documentation (EMA, FDA, etc.).

Contraindications

Adalgur N is contraindicated and must not be used in patients with a known hypersensitivity to adalimumab or any of its ingredients. It is also prohibited for patients with active tuberculosis (TB) or other severe infections, such as sepsis. The medicine is contraindicated in patients with moderate to severe heart failure (NYHA Class III/IV).

Use Restrictions and Eligibility

Eligibility is defined by age and coexisting conditions. Use is restricted in patients with certain conditions and requires specific clinical assessment before starting treatment:

Population Group	Regulatory Status / Rule
Active or Latent TB	Must be screened for TB; latent TB must be treated prior to initiating therapy.
HBV Carriers	Requires close monitoring during and after treatment; must stop therapy if HBV reactivation occurs.
Demyelinating Disorders	Use with caution due to risk of new onset or exacerbation (e.g., Multiple Sclerosis).
Age Groups	Pediatric eligibility varies by condition, ranging from ge 2 years for some uses (e.g., JIA) to ge 12 years for others (e.g., Hidradenitis Suppurativa).
Pregnancy	Use only if clearly needed. Infants exposed *in utero* should not receive live vaccines for 5 months after the mother's last dose.

What should I know about interactions with other medicines?

Adalgur N contains two active substances, paracetamol and thiocolchicoside, and its interaction profile combines warnings related to both components, along with specific constraints regarding the reproductive process.

Documented Drug and Substance Interactions

Other Analgesics (Pain Relieving Medicines): The medicine should not be used in combination with other analgesics without consulting a healthcare professional.
Alcohol (Ethanol): Consumption of alcohol increases the risk of hepatotoxicity (liver damage) associated with the paracetamol component.
Flucloxacillin (Antibiotic): Concomitant use with flucloxacillin carries a risk of developing a severe metabolic disorder called high anion gap metabolic acidosis, which requires urgent medical attention. This risk is notably elevated in individuals with underlying conditions such as severe kidney failure, sepsis, malnutrition, or chronic alcoholism.

Interaction with Clinical Tests and Conditions

Laboratory Tests: The medication may alter the results of certain laboratory tests, including blood, urine, and allergy skin tests. Individuals should inform the laboratory or healthcare provider that they are taking this medicine before any testing.
Contraception Requirement (Thiocolchicoside Component): Due to the potential for one of the thiocolchicoside metabolites to cause damage to cell chromosomes (aneuploidy), a strict constraint is placed on its use. Women of childbearing potential must use highly effective contraception during treatment and for a specified period after cessation. Men should also follow contraceptive advice and be advised against conceiving children during treatment and for three months afterward.

Mechanism of Action

Central Dampening of Nociceptive Signal Transmission

The analgesic component works primarily in the central nervous system (CNS), engaging multiple molecular targets. Its active metabolite indirectly modulates Cannabinoid (CB1) and TRPV1 receptors while also inhibiting central Cyclooxygenase (COX) enzymes. This multi-target action enhances the body's natural descending inhibitory pathways, leading to a physiological attenuation of nociceptive signal propagation within the central nervous system.

Modulation of Spinal Motor Neuron Excitability

The muscle relaxant component exerts its effect centrally by modulating inhibitory signals at the spinal level. Its active metabolite interacts with inhibitory systems, notably the Glycine Receptor (GlyR), which enhances the inhibitory input motor neurons receive. This modulation of inhibitory spinal reflexes consequently lowers the excessive reflex excitability of motor neurons. The enhanced inhibition results in a physiological reduction in skeletal muscle tone and contracture.

Pharmacodynamic Synergy

The two mechanisms are complementary and target distinct physiological processes: nociceptive signaling and motor neuron excitability. By acting on both nociceptive signal processing and motor neuron excitability, the combined mechanisms address the elements of the spasm-pain cycle. This simultaneous modulation produces a coordinated physiological effect. The analgesic component's COX inhibition is constrained in contexts characterized by high levels of peripheral inflammatory mediators.

Dosage and Administration Information

How to Use Adalgur N

The following are the standard administration procedures and dosing constraints for Adalgur N (Paracetamol and Thiocolchicoside) tablets. This information is procedural and does not include therapeutic benefits or safety details.

Administration and Dosing Protocol

The route for this combination medicine is oral. Adalgur N is supplied as a tablet that must be swallowed whole with a glass of water, and it can be taken either with or after food.

Instruction Category	Requirement
Route of Administration	Oral (Tablet)
Adult Unit Dose	1 to 2 tablets per administration
Maximum Daily Frequency	Up to 4 times per day, with a minimum interval of 6 hours between doses.
Duration of Use	Strictly limited to short-term use, not exceeding seven consecutive days.

Population-Specific Use Restrictions

Standard protocols define specific restrictions based on patient population:

Children and Adolescents: Adalgur N is not recommended for use in individuals under 16 years of age.
Hepatic Impairment: Dose reduction for the Paracetamol component is necessary for patients with impaired liver function.

Summary of the Use Protocol

The combination of a maximum daily frequency and a mandatory 6-hour interval establishes the dosing schedule. The maximum duration constraint of seven days is a component of the use protocol, which specifies that the medicine is administered only for acute, limited periods.

Recent Clinical Evidence

Clinical Studies for Acute Muscle Contractures

The clinical evaluation of Adalgur N relies primarily on Randomized Controlled Trials (RCTs), the primary study type used for evaluating medicines. The evidence base includes systematic reviews and meta-analyses, which combine data from multiple RCTs.

The combination was studied for its use alongside other established forms of care, relevant in conditions presenting with cycles of stability and flare-ups. Research explored short-term changes during periods of increased symptom activity, focusing on outcomes related to physical discomfort and functional limitations, relevant to acute low back pain (lumbago) or cervical pain. Research describes patterns observed related to how symptoms evolved in the studied populations.

What the Core Research Examined

Researchers set out to examine two main areas: changes in pain and changes in functioning. The primary outcomes studied included evaluation of pain intensity, typically assessed using patient-reported visual or numerical scales. Studies explored outcomes reflecting daily functioning or activity level by monitoring changes in physical limitations.

By measuring these objective and patient-reported outcomes, studies help show what has been observed so far about acute symptom patterns. Researchers also monitored the consumption of rescue analgesic medication to gather additional data relevant to outcomes related to physical discomfort during the study periods.

Duration of Evidence and Long-Term Use

The evidence base is relevant in trials assessing short-term or episodic symptom patterns. The follow-up durations were limited; most trials monitored patient responses over defined time intervals of only five to seven consecutive days. Long-term effects are not established. Information is limited for outcomes beyond the acute phase, and certainty remains low regarding sustained use. Regulatory documents indicate that prolonged treatment has not been established.

Evidence in Specific Patient Groups

The majority of the research has focused on adults experiencing acute episodes of muscle spasm, and regulatory findings indicate the research scope generally encompasses adolescents from 16 years of age.

However, data for certain groups remain insufficient. For instance, limited information is available concerning the use of the combination in special populations, such as older adults. Regulatory documents confirm that data for certain subgroups, particularly vulnerable populations, remain insufficient and these groups were not studied in the core clinical research.

Overall Evidence Consistency and Research Gaps

Scientific reviewers note that the evidence quality varies across studies, and some meta-analyses indicate that the observed symptom changes may be small in magnitude. Key research limitation frames include the fact that follow-up durations were limited, restricting the applicability of findings to the acute treatment window. The overall evidence level is classified as Moderate. This classification accounts for the existence of multiple trials while noting methodological concerns and the absence of established long-term data. Research currently emphasizes data collected during the initial treatment phase.

Frequently Asked Questions (FAQ)

Common questions about Adalgur N (FAQ)

Q: What are the signs of a severe allergic reaction to Adalgur N that I should watch out for?

A: Official guidance is to seek immediate medical attention if you experience signs of a severe allergic reaction (anaphylaxis). These signs may include hives, trouble breathing, swelling of the face, throat, or tongue, and a rash that spreads and causes blistering. These symptoms are considered serious and require urgent attention.

Q: Is Adalgur N known to cause stomach upset or nausea?

A: Regulatory sources for the components indicate that side effects may include stomach pain and diarrhea, and nausea or vomiting have also been reported. If you experience these effects, it is advised to continue to follow the administration instructions found in the product labeling.

Q: Will Adalgur N affect my ability to drive or operate machinery?

A: Official labeling advises against driving or operating machinery if you experience side effects like drowsiness (somnolence), due to the medicine's potential central nervous system effects. Caution should be exercised until you know how Adalgur N affects you.

Q: Can Adalgur N be taken if I am already consuming caffeine regularly?

A: Regulatory warnings focus on known drug-drug interactions, and a direct interaction with caffeine is not typically listed. However, it is worth noting that using other products containing caffeine could potentially contribute to central nervous system effects like restlessness or insomnia.

Q: What is the risk of dependence or addiction with Adalgur N?

A: Official product information does not typically discuss dependence for this type of medication. However, it is important to note the strict limit on duration (maximum of seven days) mandated by regulatory bodies due to specific component safety requirements for the Thiocolchicoside component.

Q: Has there been recent research on the long-term safety of the active ingredients in Adalgur N?

A: Official product information confirms that the clinical evidence for Adalgur N focuses on its short-term use for acute episodes, typically up to seven days. Regulatory documents explicitly state that the long-term effects and safety profile of this medicine are not established.

Q: What should I do if I accidentally miss a dose of Adalgur N?

A: Official regulatory instructions state that you should not take a double dose to compensate for a missed dose. You should continue with the next scheduled dose, ensuring you respect the minimum six-hour interval between doses.

Q: Can Adalgur N be taken on an empty stomach?

A: The administration protocol advises taking the tablet with or after food. While taking it with food may help reduce the risk of gastrointestinal upset, official labeling does not specify restrictions related to an empty stomach.

Q: Why is Adalgur N mentioned with warnings about metabolic acidosis in some patient information?

A: This specific warning is due to the interaction between the Paracetamol component of Adalgur N and the antibiotic Flucloxacillin. This interaction can interfere with the body's normal metabolic processes, potentially leading to a severe metabolic disorder known as high anion gap metabolic acidosis.

Q: Does Adalgur N help with inflammation, or is it purely for pain and muscle relaxation?

A: Adalgur N is classified as a centrally acting muscle relaxant and an analgesic (pain reliever). While its primary uses are for pain and spasm relief, the anti-inflammatory action of the analgesic component is considered modest. It is not classified as a primary anti-inflammatory drug.

Q: Are there any known issues with Adalgur N causing skin reactions or rashes?

A: Yes, official adverse reaction reports list skin reactions such as hives (urticaria) and itching (pruritus) as uncommon side effects. Severe skin reactions have also been documented, and official labeling states that if you develop a rash, you should seek medical attention.

How should Adalgur N be stored and disposed of?

Official Storage and Disposal Instructions

Adalgur N must be stored strictly according to the conditions described in the official regulatory labeling to ensure product stability and safety.

Domain	Required Conditions (Regulatory Standard)
Temperature	Store below 30 C (room temperature standard).
Protection	Keep the product in the original package and the container tightly closed to protect it from moisture.
Child Safety	Keep this medicine out of the sight and reach of children and pets.
Stability	Do not use the medicine after the expiry date (EXP) stated on the carton.
Disposal	Do not throw away unused or expired medicine via wastewater or household waste; dispose of the product in accordance with local regulatory requirements.